COVID-19 T-cell immune response map, immunoSEQ T-MAP COVID for research of T-cell response to SARS-CoV-2 infection

Reporter: Aviva Lev-Ari, PhD, RN


Read our latest blog | T cells: Understanding Exposure and Immunity to COVID-19 by Adaptive Co-Founder and CSO, Harlan Robins. Read here

Watch the video

T cells are the adaptive immune system’s first responders to any virus, circulating in the blood to detect and quickly multiply to attack the virus, often before symptoms appear. Adaptive Biotechnologies’ unique MIRA Technology and immunoSEQ Technology has enabled us to create a comprehensive view of the T-cell response to SARS-CoV-2 infection. This data has been made public as part of the ImmuneCODE Initiative in order to help propel drug, vaccine, and clinical trial research. We are launching immunoSEQ T-MAP COVID with the tools to study and analyze the COVID-19 T-cell immune response map.

SARS-CoV-2-specific Antigen-TCR sequence-level data
Quantitative sequence level data for TCR repertoires for SARS-CoV-2 specific antigens
Monitor immunologic response to SARS-CoV-2 infection or vaccine
Track COVID-19 specific TCR sequences longitudinally
Dive into Patient, Population, or Cohort-level data
Determine TCR clones shared between cohorts & those that are Public vs Private clones


Learn more about the science behind the ImmuneCODE database in our first publication (Nolan et al.) and to discover initial COVID-19 data insights, read our recently updated pre-print publication (Snyder et al.)

A large-scale database of T-cell receptor beta (TCRβ) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2

Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels

End-to-end solution; from experimental design to publication ready data

SARS-CoV-2-specific TCR repertoire sequences & antigen data

✔  Validated TCR-antigen data from over 70 MIRA experiments

✔  In vivo identified SARS-CoV-2-specific TCR sequences

✔  TCR-Antigen sequence level data with the PCR, bias-controlled, reproducible immunoSEQ Assay

Data analysis through the immunoSEQ Analyzer or Computational Biology Services

✔  Explore SARS-CoV-2-specific TCR-Antigen sequence data in the immunoSEQ Analyzer

✔  Compare your COVID-19 samples against our COVID-19 samples to identify public vs private clones

✔  Computational Biology Services for COVID-19 data and Metadata analysis

Comprehensive COVID-19 TCR-Antigen sequence database

✔  Providing you a comprehensive view of SARS-CoV-2-specific antigen and TCR level data

✔  Database will constantly be updated with new findings and TCR-Antigen sequence data


Check out the publications below to learn how researchers are propelling their COVID-19 research by leveraging immunoSEQ T-MAP COVID and the ImmuneCODE COVID-19 database

Analysis of SARS-CoV-2 specific T-cell receptors in ImmuneCode reveals cross-reactivity to immunodominant Influenza M1 epitope


Watch our video, about how the immunoSEQ Technology and immunoSEQ T-MAP COVID can be used to better understand the immune response to SARS-CoV-2 infection.


Ready to learn more about how our immunoSEQ T-MAP COVID service can help you propel your research forward? Contact us below to speak with one of our experts.




Nanoparticles can turn off genes in bone marrow cells

Reporter : Irina Robu, PhD

MIT engineers developed an alternative to turn off specific genes which play a vital role in producing blood cells of the bone marrow using specialized nanoparticles. These nanoparticles can be made-to-order to treat heart disease or increase the yield of stem cells in patience who need stem cell transplants. The particles are coated with lipids that help stabilize them, and they can target organs such as the lungs, heart, and spleen, depending on the particles’ composition and molecular weight. This genetic therapy, also known as RNA interference is difficult to target organs other than the liver, where most of the nanoparticles tend to collect.

RNA interference is an approach that could theoretically be used to treat a variety of diseases by delivering short strands of RNA that block specific genes from being turned on in a cell. Yet, the main obstacle to this kind of therapy has been  delivering it to the right part of the body. When injected into the bloodstream, nanoparticles carrying RNA tend to accrue in the liver, which various biotech companies have taken advantage of to develop new experimental treatments for liver disease.

In their recent study, scientists set out to adapt the nanoparticles so that they could reach the bone marrow which contains stem cells that produce different types of blood cells. Stimulating the process , they could enhance the yield of hematopoietic stem cells for stem cell transplantation and they created variants that have different arrangements of surface coating, polyethylene glycol. They were able to test 15 particles and determined one that was able to avoid being caught in the liver or the lungs, and that could effectively accumulate in endothelial cells of the bone marrow. They also showed that RNA carried by this particle could reduce the expression of a target gene by up to 80 percent.

The scientists then tested this approach with two genes. The first gene, SDF1 is a molecule that normally prevents hematopoietic stem cells from leaving the bone marrow. They realized that turning off the SDF1 gene could have the same effect as the drugs that are being used to induce hematopoietic stem cell release in patients who need undergo radiation treatments for blood cancers. These stem cells are later transplanted to repopulate the patient’s blood cells. By knocking down SDF1, they could boost the release of hematopoietic cells fivefold which is comparable to the levels achieved by the drugs that are now used to enhance stem cell release.

The second gene researchers use is MCP1, a molecule that plays a key role in heart disease.  They realized that when MCP1 is released by bone marrow cells after a heart attack, it stimulates a flood of immune cells to leave the bone marrow and travel to the heart. Researchers realize that by delivering RNA that targets MCP1 reduced the number of immune cells that went to the heart after a heart attack.

Using these new particles, researchers hypothesized that they could further develop treatments for heart disease and other conditions.



The complication of Pfizer’s Vaccine Distribution’s Plan

Reporter : Irina Robu, PhD

Even though Pfizer announcing the development of safe and effective vaccine is cause for celebration, scientists and public experts face  the challenge of how to quickly make millions of doses of the vaccine and getting them to hospitals, clinics and pharmacies. But Pfizer distribution of vaccines rely on a network of companies, federal and state agencies and on the ground health workers in the midst of a pandemic that is spreading at a high rate in United States.

Before Pfizer can begin shipping its vaccine, federal and state governments must inform Pfizer of how many doses are needed along with syringes, needles and other supplies needed to administer the vaccine. In addition, employees at the locations should be trained to store and administer the vaccine and to ensure that after people are vaccinated, they return for a second dose.

The complication of Pfizer’s vaccine is that it has to be stored at minus 70 degree Celsius until before it is injected.  Pfizer is making the vaccine at facilities in Kalamazoo, Mich., and Puurs, Belgium. The doses distributed in the United States will mostly come from Kalamazoo. When they receive emergency authorization from FDA, Pfizer will send limited doses to large hospitals, pharmacies and other vulnerable groups. At the same time, nine other candidates are also in the final stage of testing.

In Kalamazoo, vaccines will go into vials, vi will go into trays (195 vials per tray) and the trays will go into specially designed cooler-type boxes (up to five trays per box).The reusable boxes, each toting between 1,000 and 5,000 doses and stuffed with dry ice, are equipped with GPS-enabled sensors. Pfizer employees will be able to monitor the boxes’ locations and temperatures as FedEx and UPS transport them to hospitals and clinics nationwide.

The minute Pfizer coolers reach their destinations, hospitals or pharmacies will have a few alternatives of  how to store the vaccine. The easiest option is using ultracold freezers, but they can stash the trays in conventional freezers for up to five days. The destinations can keep the vials in the cooler for up to 15 days as long as they replenish the dry ice and don’t open it more than twice a day.

The chief executives at Pfizer and BioNTech suggest that Pfizer is able to produce up to 50 million doses per year and only half of those will go to US. But since two doses are needed for each person, only 12.5 million doses can be vaccinated.

The other challenge is distributing the vaccine in rural areas, where if not administering the doses fast enough it can go bad. Even though Pfizer has developed and tested an effective vaccine, figuring out how to distribute it is the hardest challenge Pfizer will face.


Regeneron’s new antibody cocktail drug, REGN-COV2

Reporter : Irina Robu, PhD

Regeneron,  leading biotechnology company using the power of science to bring new medicines to patients in need answered quickly to the COVID-19 pandemic and found an antibody cocktail  as the pandemic numbers increase in the U.S. The antibody cocktail, also known as REGN-COV2 antibody combination therapy is an investigational medicine, and its safety and efficacy have not been fully evaluated by any regulatory authority.

REGN-COV2 is being studied in four ongoing late-stage clinical trials: two Phase 2/3 trials for the treatment of hospitalized and non-hospitalized COVID-19 patients, Phase 3 RECOVERY trial of hospitalized COVID-19 patients in the UK, and a Phase 3 trial for the prevention of COVID-19 in uninfected people who are at high-risk of exposure to a COVID-19 patient. The Phase 3 prevention trial is being jointly conducted with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

The company expects approval from FDA on its antibody cocktail and expect to have 2.4-gram doses ready for about 80,000 patients at the end of November and 200,000 doses at the beginning of January.  At the same time, Regeneron partnered with Roche to expand its capacity further by increasing its manufacturing capacity.

Regeneron come in COVID-19 research early this year as the outbreak was in its early stages, testing hundreds of virus-neutralizing antibodies in mice and seeing how they compared with antibodies from human survivors of the novel coronavirus.




McKinsey experts on COVID-19: Implications for business



Reporter on Highlights: Joel T. Shertok, PhD

JTS – 11/17/20


  • COVID-19-vaccine trial: a leading candidate has an efficacy rate of about 90 percent.
  • The gap between incoming and outgoing Treasury funds may reach $30 trillion soon.
  • Our latest research shows a particularly effective bridge for governments to consider: real estate.
  • Many businesses will embrace sustainability; voluntary carbon markets can help them reach their goals.
  • China, the world’s growth engine for the past 25 years, has come back
  • Consumer behavior has changed, pockets of growth are shifting, and leadership and management practices are in flux
  • Likely Pandemic scenarios:
  • A muted recovery
  • A prolonged and insufficient recovery
  • As the unrelenting COVID-19 pandemic rolls on, the future isn’t what it used to be: what used to be a simple idea now comes freighted with caveats, assumptions, and speculations.
  • The auto industry is one of the world’s largest and has been devastated by the pandemic: sales may drop by 20 to 30 percent in 2020, and we estimate that profits will fall by $100 billion.
  • The US restaurant industry has given many iconic brands to the rest of the world. But today, the sector is in trouble.
  • People don’t order sides, appetizers, and desserts as frequently when they’re ordering for delivery—but as leaders know, those items are often the difference between profit and loss.
  • For banks, the pandemic has changed everything. Risk-management teams are running hard to catch up with cascades of credit risk, among other challenges.
  • Ethnic minority groups have made progress. But the COVID-19 crisis threatens that progress;
  • All ethnic-minority groups have higher age-adjusted COVID-19-related death rates than white people do.
  • In the middle of the deepest recession in memory, stock markets are reaching new highs. Why the disconnect?
  • Many investors still take a long-term perspective; they are looking ahead to the end of the pandemic.
  • Another factor: five big-tech companies now make up 21 percent of the S&P 500,
  • The overall stock market can do relatively well even when employment and GDP are severely depressed.
  • Companies can expect a disruption to their production lines of one to two months—a very long time.
  • The effects of the COVID-19 crisis have exacerbated gender disparities and their implications for women at work, especially for mothers, female senior leaders, and Black women across America.
  • The exodus might include as many as two million women. That would raise a significant barrier to achieving gender parity in leadership roles in years to come.
  • The global economic contractions resulting from the COVID-19 pandemic have far exceeded those of the Great Recession that ended in 2009 and have occurred at a much faster rate, hitting all sectors and many of the world’s largest employers.
  • Two important issues facing healthcare providers. First, similarities in flu and COVID-19 symptoms could lead to a threefold spike in demand for COVID-19 testing as flu season in the Northern Hemisphere approaches.
  • Second, the crisis has also led to a surgical backlog for elective procedures because of lack of hospital capacity, workforce shortages, and new safety protocols.




Leveraging Clinical Narrative Text at Scale: Applying Natural Language Processing to Understand the Patient Care Experience @NIH.gov


News & Events


Leveraging Clinical Narrative Text at Scale: Applying Natural Language Processing to Understand the Patient Care Experience @NIH.gov

November 5, 2020
1:00 – 2:30 pm EST

Leveraging Clinical Narrative Text at Scale

View WebinarExternal Web Site Policy


Recent advances in biomedical informatics, such as the application of machine learning and natural language processing (NLP) to Electronic Health Record (EHR) data, have resulted in breakthroughs in the ability to identify, classify, and predict aspects of patient care, symptoms, and communication in the clinical record. These new tools that allow researchers and clinicians to generate and examine new research questions examining patient care quality and health-related quality of life.

This webinar presents four research studies highlighting different NLP applications in EHR free text. Topics include (1) phenotyping for treatment-related side effects and system severity, (2) cancer treatment-related side-effects, (3) non-adherence to cancer therapy and recurrence, and (4) documentation of patient care goals.

Presenters discuss how these methodologies support the capture and use of real-world data for precision oncology care, population health management, and how to scale-up applications within and across health care systems.


Julian Hong, MD, MS
Assistant Professor
Healthcare Delivery Research Program
Department of Radiation Oncology
UCSF Medical Center

Charlotta Lindvall, MD, PhD
Instructor, Medicine, Harvard Medical School
Physician, Department of Psychosocial Oncology and Palliative Care
Dana-Farber Cancer Institute

Tina Hernandez-Boussard, PhD
Associate Professor
Stanford University School of Medicine

Imon Banerjee, PhD
Assistant Professor
Department of Biomedical Informatics
Emory University School of Medicine

Intended Audience

Extramural investigators at junior, mid, and senior levels. Basic familiarity with data science methods may be helpful, but not required.

For more information, please contact Roxanne Jensen.

This webinar will be archived on the HDRP Events webpage.


From: <messenger@webex.com>

Reply-To: <jennifer.leidenberger@nih.gov>

Date: Wednesday, November 18, 2020 at 4:09 PM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: Resources from the November 5 Leveraging Clinical Narrative Text at Scale Webinar

re:Invent 2020 – Virtual 3 weeks Conference, Nov. 30 – Dec. 18, 2020: How Healthcare & Life Sciences leaders are using AWS to transform their businesses and innovate on behalf of their customers. 


Preview the tracks that will be available, along with the general agenda, on the website. 





AWS re:Invent 2020 – Life Sciences Attendee Guide

AWS re:Invent routinely fills several Las Vegas venues with standing-room only crowds, but we are bringing it to you with an all-virtual and free event this year. This year’s conference is gearing up to be our biggest yet and we have an exciting program planned with five keynotes, 18 leadership sessions, and over 500 breakout sessions beginning November 30. Hear how AWS experts and inspiring members of the Life Sciences & Genomics industry are using cloud technology to transform their businesses and innovate on the behalf of their customers.For Life Sciences attendees looking to get the most out of their experience, follow these steps:

  • Register for re:Invent.
  • Take a look at all of the Life Sciences sessions available, as well as lots of other information and additional activities, in our curated Life Sciences Attendee Guide coming soon!
  • Check back on this post regularly, as we’ll continually update it to reflect the newest information.

Life Sciences at re:Invent 2020

AWS enables pharma and biotech companies to transform every stage of the pharma value chain, with services that enhance data liquidity, operational excellence, and customer engagement. AWS is the trusted technology provider with the cost-effective compute and storage, machine learning capabilities, and customer-centric know how to help companies embrace innovation and bring differentiated therapeutics to market faster.

Life Sciences sessions

Bookmark this blog and check back for direct links to each session and add to your re:Invent schedule as soon as the session catalog is released:

LFS201: Life Sciences Industry: Executive Outlook
Learn how AWS technology is helping organizations improve their data liquidity, achieve operational excellence, and enhance customer engagement.

LFS202: Improving data liquidity in Roche’s personalized healthcare platform
Learn how Roche’s personalized healthcare platform is accelerating drug discovery and transforming the patient journey with digital technology.

LFS302: AstraZeneca genomics on AWS: from petabytes to new medicines
Learn how AstraZeneca built an industry leading genomics pipeline on AWS to analyze 2 million genomes in support of precision medicine.

LFS303: Building patient-centric virtualized trials
Learn how Evidation Health architects on AWS to create patient-centric experiences in decentralized and virtual clinical trials.

LFS304: Streamlining manufacturing and supply chain at Novartis
Learn how Novartis is creating real-time analytics and transparency in the pharma manufacturing process and supply chain to bring innovative medicines to market.

LFS305: Accelerating regulatory assessments in life sciences manufacturing
Learn how Merck leveraged Amazon Machine Learning to build an evaluation and recommendation engine for streamlining pharma manufacturing change requests.

Other related sessions of interest:

ENT203: How BMS automates GxP compliance for SAP systems on AWS

GPS211: AWS Partners driving innovation amidst COVID-19

HLC203: Securing Personal Health Information and High Risk Data Sets

WPS202: Transform research environments with Service Workbench on AWS

AIM310: Intelligent document processing for healthcare organizations

Healthcare Attendee Guide

AWS re:Invent routinely fills several Las Vegas venues with standing-room only crowds, but we are bringing it to you with an all-virtual and free event this year. This year’s conference is gearing up to be our biggest yet and we have an exciting program planned for the Healthcare industry with five keynotes, 18 leadership sessions, and over 500 breakout sessions beginning November 30. See how AWS experts and talented members of the Healthcare industry are using cloud technology to transform their businesses and innovate on the behalf of their customers.For Healthcare attendees looking to get the most out of their experience, follow these steps:

  • Register for re:Invent.
  • Take a look at all of the Healthcare sessions available, as well as lots of other information and additional activities, in our curated Healthcare Attendee Guide coming soon!
  • Check back on this post regularly, as we’ll continually update it to reflect the newest information.

Healthcare at re:Invent 2020

AWS is the trusted technology partner to the global healthcare industry. For over 12 years, AWS has established itself as the most mature, comprehensive, and broadly adopted cloud platform and is trusted by thousands of healthcare customers around the world—including the fastest-growing startups, the largest enterprises, and leading government agencies. The secure and compliant AWS technology enables the highly regulated healthcare industry to improve outcomes and lower costs by providing the tools to unlock the potential of healthcare data, predict healthcare events, and build closer relationships with patients and consumers. The healthcare track at re:Invent 2020 will feature customer-led sessions focused on these each of these critical components, accelerating the transformation of healthcare.

Healthcare sessions

Learn more and bookmark each Healthcare session:

HCL201: Healthcare Executive Outlook: Accelerating Transformation
Learn how AWS is working with industry leaders to increase their pace of innovation, unlock the potential of their healthcare data, help predict patient health events, and personalize the healthcare journey for their patients, consumers, and members.

HLC202: Making Healthcare More Personal with MetroPlus Health
Learn how MetroPlus Health leveraged AWS technology to quickly build and deploy an application that personally and proactively reached out to its members during a time of critical need.

HLC203: Securing Personal Health Information and High Risk Data Sets
Learn how Arcadia developed a HITRUST CSF Certified platform by leveraging AWS technology to enable the secure management of data from over 100 million patients.

HLC204: Accelerating the Transition to Virtual Care with AWS
Learn how MedStar Health developed and deployed two call centers in less than week that are supporting more than 3,500 outpatient telehealth sessions a day.

WPS202: Transform research environments with Service Workbench on AWS
Learn how Harvard Medical School is using AWS to procure and deploy domain-specific data, tools, and secure IT environments to accelerate research.

WPS209: Reinventing medical imaging with machine learning on AWS
Learn how Radboud University Medical Center uses AWS to power its machine learning imaging platform with 45,000+ registered researchers and clinicians from all over the world.

WPS211: An introduction to healthcare interoperability and FHIR Works on AWS
Learn about AWS FHIR Works, an open-source project, designed to accelerate the industries use of the interoperability standard, Fast Healthcare Interoperability Resources (FHIR).

WPS304: Achieving healthcare interoperability with FHIR Works on AWS
Learn how Black Pear Software leveraged AWS to build an integration toolkit to help their customers share healthcare data more effectively.

Extras you won’t want to miss out on!

LFS201: Life Sciences Industry: Executive outlook

LFS202: AstraZeneca genomics on AWS: From petabytes to new medicines

LFS303: Building patient-centric virtualized trials

AIM303: Using AI to automate clinical workflows

AIM310: Intelligent document processing for the insurance industry

INO204: Solving societal challenges with digital innovation on AWS

ZWL208: Using cloud-based genomic research to reduce health care disparities

GPS211: AWS Partners driving innovation amidst COVID-19

Data Architecture for Blockchain Deployment of Digital Assets: LPBI IP Asset Classes I,II,III

Author: Aviva Lev-Ari, PhD, RN


Distinction between A and B, below

  • A.  1.0 LPBI – 2012–2020 – IP Assets available for sale

  • B.  2.0 LPBI – 2021–2025 – IP Assets under construction – WILL BE AVAILABLE FOR SALE


A.  1.0 LPBI – 2012–2020 – IP Assets available for sale


A.1 A List of Scientific articles N=6,000 

STORED in Excel file run on 6/30/2020 and 12/31/2020


They need to be Indexed by several keys:

A.1.1  Author Name

A.1.2  Article Title

A.1.3  Category of Research, see article example , below

For the Cancer category

  • we have the following tree structure
  • System had data on how many articles are in each category
  •  Cancer – General
  •  Cancer and Current Therapeutics
    •  interventional oncology
      •  Breast Cancer – impalpable breast lesions
      •  Prostate Cancer: Monitoring vs Treatment
  •  CANCER BIOLOGY & Innovations in Cancer Therapy
    •  Anaerobic Glycolysis
    •  Cachexia
    •  Cancer Genomics
      •  Circulating Tumor Cells (CTC)
        •  Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood
          •  mRNA
        •  MagSifter chip
      •  KRAS Mutation
      •  Li-fraumeni syndrome.
      •  TP53 – Germline mutations
    •  cancer metabolism
    •  Funding Opportunities for Cancer Research
    •  Genomic Expression
    •  Glioblastoma
    •  Hexokinase
    •  Loss of function gene
    •  Metabolic Immuno-Oncology
    •  Metastasis Process
    •  Methylation
    •  Microbiome and Responses to Cancer Therapy
    •  Monoclonal Immunotherapy
    •  mtDNA
    •  Oxidative phosphorylation
    •  Pancreatic cancer
    •  Pyruvate Kinase
    •  The NCI Formulary
    •  tumor microenvironment
    •  Warburg effect
  •  Cancer Informatics
  •  Cancer Prevention: Research & Programs
  •  Cancer Screening
  •  Cancer Vaccines: Targeting Cancer Genes for Immunotherapy
    •  Engineering Enhanced Cancer Vaccines

A.1.4  Type of article: by the role of the author: 

  • If the Author is Curator THAN this article is a curation
  • If the Author is Reporter THEN this article is a Scientific reporting article

A.1.5  Article Abstract will be a WordCloud created by ML – one image per article


Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?  <<<<<<<<< Article Title

Author: Larry H. Bernstein, MD, FCAP  <<<<<<<<< Author’s Name

https://pharmaceuticalintelligence.com/2012/10/17/is-the-warburg-effect-the-cause-or-the-effect-of-cancer-a-21st-century-view/   <<<<<<< URL

  • The system provides: “Related” what you named associated, see below  will need to be placed in the article description
  • The system provides: “Posted in” – meaning  ALL the categories of research checked off by the author that this article belong to by the SUBJECT MATTER of the article

EXAMPLE for Related” what you named associated


What can we expect of tumor therapeutic response?

In “Biological Networks, Gene Regulation and Evolution”

WordCloud Visualization of LPBI’s Top Twelve Articles by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com

In “Academic Publishing”

AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo

In “Biological Networks, Gene Regulation and Evolution”

Examples for >>>>>>>> Category of Research  live links listing in parenthesis number of articles in one category

Posted in Biological NetworksCANCER BIOLOGY & Innovations in Cancer TherapyCell BiologyDisease BiologyGenome BiologyImaging-based Cancer Patient ManagementInternational Global Work in PharmaceuticalLiver & Digestive Diseases ResearchMetabolomicsMolecular Genetics & PharmaceuticalNutritionPharmaceutical Industry Competitive IntelligencePharmaceutical R&D InvestmentPopulation Health ManagementProteomicsStem Cells for Regenerative MedicineTechnology Transfer: Biotech and Pharmaceutical | Tagged Adenosine triphosphateATPGlycolysisHypoxia-inducible factorsKrebLactate dehydrogenaseMammalian target of rapamycinMitochondrionWarburg Effect | 40 Comments

Below, an excerpt from the 6,000 LIST: Top Posts by VIEWS for all days ending 2020-06-02 (Summarized)


All Time      
Title Views Author Name Type of Article
Home page / Archives 676,690 Internet Access Tabulation
Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? 17,117 Larry H. Bernstein, MD, FACP Investigator Initiated Research
Recent comprehensive review on the role of ultrasound in breast cancer management 14,242 Dr. D. Nir Commission by Aviva Lev-Ari, PhD, RN
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) 13,839 Dr. Pearlman, MD, PhD, FACC & Aviva Lev-Ari, PhD, RN Commission by Aviva Lev-Ari, PhD, RN
Paclitaxel vs Abraxane (albumin-bound paclitaxel) 13,709 Tilda Barliya, PhD Investigator Initiated Research
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications 8,230 Aviva Lev-Ari, PhD, RN Investigator Initiated Research
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care 7,903 Dr. Pearlman, MD, PhD, FACC & Aviva Lev-Ari, PhD, RN Investigator Initiated Research
Mesothelin: An early detection biomarker for cancer (By Jack Andraka) 6,540 Tilda Barliya, PhD Investigator Initiated Research
Our TEAM 6,505 Internet Access Tabulation
Biochemistry of the Coagulation Cascade and Platelet Aggregation: Nitric Oxide: Platelets, Circulatory Disorders, and Coagulation Effects 5,221 Larry H. Bernstein, MD, FACP Investigator Initiated Research
Interaction of enzymes and hormones 4,901 Larry H. Bernstein, MD, FACP Commission by Aviva Lev-Ari, PhD, RN
Akt inhibition for cancer treatment, where do we stand today? 4,852 Ziv Raviv, PhD Investigator Initiated Research
AstraZeneca’s WEE1 protein inhibitor AZD1775 Shows Success Against Tumors with a SETD2 mutation 4,535 Stephen J. Williams, PhD Investigator Initiated Research
The History and Creators of Total Parenteral Nutrition 4,511 Larry H. Bernstein, MD, FACP Commission by Aviva Lev-Ari, PhD, RN
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses 4,365 Zohi Sternberg, PhD Investigator Initiated Research
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules 4,188 Stephen J. Williams, PhD Investigator Initiated Research
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets 4,038 Dr. Pearlman, MD, PhD, FACC, Larry H. Bernstein, MD, FACP & Aviva Lev-Ari, PhD, RN Commission by Aviva Lev-Ari, PhD, RN
Founder 3,895 Aviva Lev-Ari, PhD, RN Investigator Initiated Research


A.2 A List of 16 e-BOOKS



A.2.1   Each book is made of articles included in the N=6,000

A.2.2 Books will list the URL of each book

















A.3 A List of e-Proceedings and Tweet Collections

A.3.1 each entry is an article included in N=6,000

B.   2.0 LPBI – 2021–2025 –

IP Assets under construction –



B.1 Journal articles

  • Will be subjected to ML and a NEW product will be created
  • Instead of N=6,000 article – we will have N= 6,000 Medical INSIGHTS

B.2 16 e-Books

  • Will be subjected to ML and a NEW product will be created
  • Instead of 16 Books – we will have 16 COLLECTIONS of Medical INSIGHTS derived from Text Analysis of ONLY the articles included on each Volume
  • 16 e-Books will become 16 AUDIO BOOKS
  • 16 e-Books will become 16 Books in Japanese, Spanish and Russians


B.3 eProceedings & Tweet collections

  • Will be subjected to ML and a NEW product will be created
  • Instead of 60 e-Proceedings and 30 Tweet collections we will get 100 Business INSIGHTS Collections in the domain of each conference


We believe that Blockchain will enable STORAGE of each item that will be available for sale

  • LPBI will have team members Bundling items per customer needs 
  • Promotion can be done OUTSIDE the Blockchain system – STIRRING Customers to the Blockchain transaction system for TRADE and recording of transactions
  • That is true for A and for B, below

A.   1.0 LPBI – 2012–2020 – IP Assets available for sale

B.   2.0 LPBI – 2021–2025 – IP Assets under construction – WILL BE AVAILABLE FOR SALE


Data Architecture Questions


  1. In what data format is the content stored? In other words, is the content in image pdfs, searchable document pdfs, html, xls, word documents, text files, or some other form?

Example: TEXT

Versions of LPBI Group’s Elevator Pitch: 2.0 LPBI Group’s Team – In Our Own Words

My proposed Elevator Pitch

For the first time in the ten years of our private ownership, the opportunity to acquire the Inventor of Scientific curation has become a reality, Available for Transfer of ownership.

You can own a portfolio of Intellectual Property Assets that commands ~2MM e-Readers and offers ~6,000 of the best interpretive articles in five specialties of Medicine and Life Sciences. Pages of our 16 books have been downloaded ~125,000 times and over 100 of the top biotech and medical conferences were covered in real time and recorded in writing and Tweets. New strategies in AI and Blockchain are now applied on LPBI’s content for INSIGHT searches and pattern recognition by automated Machine Learning algorithms for use in drug discovery and drug repurposing. All of LPBI’s content was created by our Experts, Authors, Writers (EAWs).

    • We UPLOAD MS Word file NOT PDF
    • INVENTORY is stored in Excel
    • Top Posts for all days ending 2020-11-16 (Summarized)
      1. 7 Days |30 Days |Quarter |Year |All time
    • All Time
  • Title
  • Views
  • 716,030
  • 17,263
  • 15,300
  • 14,341
  • 14,006
  • 8,770
  • 8,398
  • 6,632
  • 6,580
  • 5,536
  • 5,304
  • 5,056
  • 4,899
  • 4,712
  • 4,665
  • 4,453
  • 4,416
  • 4,335
  • 4,206
  • 4,126
  • 4,118
  1. Within each content file or dataset, is the content metadata already defined, or would we need to parse the file to pull out the metadata? In other words, in the file for a journal article, do you already have the author, date, abstract, keywords, etc. defined as discrete pieces of data, or is all of this information embedded within the overall file?


They need to be Indexed by several keys:

A.1.1  Author Name

A.1.2  Article Title

A.1.3  Category of Research


  1. Do you expect to use a single type of subscription (such as a monthly subscription), or will different types of data have different types 

of subscription options (similar to how journals offer both one-time 24-hour subscriptions to a single article as well as monthly ongoing subscriptions)?

We wish to SELL ARTICLE DOWNLOAD vs Subscriptions

  1. Does the marketplace need to include fuzzy search (i.e., the ability to find content based on “similar to” criteria, instead of just exact match searches)? Does it need to present the user with related content, or only the content that was searched for?

Our system attaches to each article RELATED content

  1. We assume that the marketplace is not intended to replace your current LPBI company website? We are not scoping the quote to include a full website rebuild; it is assumed that the marketplace is separate (and your users would access the marketplace via the LPBI website).

YES – the digital store will connect to our newly to be designed web site for 2.0 LPBI on WordPress.com

  • The digital store is the FORUM to buy goods by digital download of content
  • $30 for One digital article or Audio article
  • REFERRAL to Amazon Website to buy a book or the book in AUDIO format or a book in Japanese and Spanish – Russia is not served by Amazon – we can sell directly to consumers
  • $100 download of an e-Proceedings for a Conference or the Tweet collection

For 2.0 LPBI Products

Bundles of Insights for Targeted Industries – B–to-B

  • Tier #1:  Insights for drug discovery embedded in consulting engagements
  • Tier #2:  Insights for drug repurposing embedded in consulting engagements
  • Tier #3:  Insights for Health Care Insurers embedded in consulting engagements

Bundles of insights for theScientific Community – B–to-C

First-ever living 3D printed aneurysm


Reporter : Irina Robu, PhD

A brain aneurysm is a bulge that forms in the blood vessel of your brain that could lead to severe health issues and possibly death. Brain aneurysm affect about one in 50 Americans and can lead to serious medical emergencies including stroke and brain damage.  Current treatments for brain aneurysm are limited and very invasive and can vary from person to person.

Researchers at Lawrence Livermore National Laboratory and their collaborators were able to replicate an aneurysm in vitro by 3D printing blood vessels with human cerebral cells. One of the leading engineers, William Hynes  performed an endovascular repair procedure on the printed aneurysm by inserting a catheter into blood vessel and tightly packed platinum coils inside the aneurysm sac. Afterward, the scientists introduced blood plasma into the aneurysm and identified the formation of blood clot where the coils were located and they were able to observe the post-op healing process of the endothelial cells within the vessels.

One thing that was obvious to the LLNL scientists is that computer modeling is an important step to developing patient-specific care for aneurysms based on patient’s blood vessel geometry, blood pressure and other factors. They also determined that it takes time for the new surgical technology to move from laboratory to the clinic.

The idea is if they can replicate the aneurysms as much as needed using  animal models or 3D printing, they can help find better options for aneurysms with uncontrollable geometries.  Since, the most common treatment for aneurysms is  the endovascular metal coiling approach, researchers believe  that by taking out the guesswork out of aneurysms treatment researchers can design more predictive 3D models that takes patient geometry into account.

Hynes teamed with former LLNL scientist Duncan Maitland and Amanda Randles, a former Lab computational scientist  to verify if Randles’s flow dynamic model compares with the real world. At low flow rates, scientist saw little movement of blood into the aneurysm, while an increased flow rate, resulted in a circular flow of blood throughout the aneurysm, as would be predictable in a true brain aneurysm.  

Using the data obtained from the flow dynamic model in combination with the 3D printing platform, researchers developed a potential tool for surgeons to pre-select the best coil types desirable to fully pack an aneurysm to obtain the best treatment outcome, and perform “test runs” of procedures before attempting them on the human patient.

Unlike animal models, LLNL’s platform allows scientists to directly measure the fluid dynamics inside the vessels and aneurysm while maintaining biological relevance.

In addition to patient-specific care and serving as a testbed for surgical training, researchers mentioned that the platform can improve the understanding of basic biology and the post-surgery healing response. Even though the results are promising, researchers mentioned that there is long way before their platform is applicable in a clinical environment setting.



Deep Medicine: How Artificial Intelligence Can Make Health Care Human Again


Reviewers: Aviva Lev-Ari, PhD, RN


Jun 24, 2019


123K subscribers

In his new book, Deep Medicine, Eric Topol – cardiologist, geneticist, digital medicine researcher – claims that artificial intelligence can put the humanity back into medicine. By freeing physicians from rote tasks, such as taking notes and performing medical scans, AI creates space for the real healing that occurs between a doctor who listens and a patient who needs to be heard. The counterintuitive recognition that technology can create space for compassion in the clinical setting could mean fewer burned-out doctors, more empowered patients, cost savings, and an entirely new way to approach medicine. Featuring: David Brooks, Eric Topol This conversation was recorded during Aspen Ideas: Health in Aspen, Colorado. Presented by the Aspen Institute, the three-day event opens the Aspen Ideas Festival and features more than 200 speakers engaging with urgent health care challenges and exploring cutting-edge innovations in medicine and science. Learn more at https://www.aspenideas.org